全球人類細胞治療原料市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計到 2034 年，用於細胞治療的人類原料市場規模將從 2025 年的 50.4 億美元達到 322.1 億美元，並預計從 2026 年到 2034 年將以 22.89% 的複合年成長率成長。

受先進細胞療法研發和商業化進程的推動，全球細胞治療用人源原料市場正經歷強勁成長。血清、生長因子和細胞培養基等人類來源的原料是細胞療法生產的關鍵要素。再生醫學和免疫療法領域投資的增加也顯著提升了市場需求。

關鍵成長要素包括臨床試驗的擴展、細胞療法監管核准的增加以及對個人化醫療日益成長的關注。生物製藥公司正在加強供應鏈，以確保獲得高品質且符合規範的原料。研究機構與產業相關人員之間合作的加強也進一步促進了市場發展。

展望未來，製造技術的進步以及CAR-T療法和幹細胞療法的商業化將創造巨大的機會。隨著對創新生物製藥需求的不斷成長，全球醫療保健領域用於細胞治療的人源性原料市場預計將穩步擴張。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球細胞療法用人類成分市場：依產品分類

• 市場分析、洞察與預測
• 細胞培養基
• 細胞培養用血清
• 細胞培養添加劑
• 試劑和緩衝溶液
• 其他原料

第5章：全球細胞治療用人類原料市場：依最終用途分類

• 市場分析、洞察與預測
• 生物製藥和製藥公司
• 合約研究組織 (CRO) 和合約生產組織 (CMO)
• 學術研究機構

第6章：全球細胞治療用人類成分市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Thermo Fisher Scientific Inc
  • Merck KGaA
  • Actylis
  • ACROBiosystems
  • STEMCELL Technologies Inc
  • Grifols SA
  • Charles River Laboratories International Inc
  • RoosterBio Inc
  • PromoCell GmbH
  • Danaher Corporation
  • BioIVT LLC
  • GeminiBio（Gemini Bioproducts LLC）
  • Akron Biotech
  • AllCells LLC
  • CGT Global

The Cell Therapy Human Raw Materials Market size is expected to reach USD 32.21 Billion in 2034 from USD 5.04 Billion (2025) growing at a CAGR of 22.89% during 2026-2034.

The global cell therapy human raw materials market is witnessing strong growth driven by increasing research and commercialization of advanced cell-based therapies. Human-derived raw materials such as serum, growth factors, and cell culture media are essential in manufacturing cell therapies. Rising investments in regenerative medicine and immunotherapy are significantly boosting demand.

Major growth drivers include expanding clinical trials, increasing regulatory approvals for cell therapies, and rising focus on personalized medicine. Biopharmaceutical companies are strengthening supply chains to ensure high-quality and compliant raw materials. Growing collaborations between research institutions and industry players are further supporting market development.

In the future, advancements in manufacturing technologies and increasing commercialization of CAR-T and stem cell therapies will create significant opportunities. As demand for innovative biologics rises, the cell therapy human raw materials market is expected to expand steadily across global healthcare sectors.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Cell Culture Media
• Cell Culture Sera
• Cell Culture Supplements
• Reagents & Buffers
• Other Raw Materials

By End-Use

• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutions

COMPANIES PROFILED

• Thermo Fisher Scientific Inc, Merck KGaA, Actylis, ACROBiosystems, STEMCELL Technologies Inc, Grifols SA, Charles River Laboratories International Inc, RoosterBio Inc, PromoCell GmbH, Danaher Corporation, BioIVT LLC, GeminiBio Gemini Bioproducts LLC, Akron Biotech, AllCells LLC, CGT Global
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Cell Culture Media Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Cell Culture Sera Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cell Culture Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Reagents & Buffers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Raw Materials Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Biopharmaceutical & Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. CROs & CMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Academic & Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL CELL THERAPY HUMAN RAW MATERIALS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Thermo Fisher Scientific Inc
  • 8.2.2 Merck KGaA
  • 8.2.3 Actylis
  • 8.2.4 ACROBiosystems
  • 8.2.5 STEMCELL Technologies Inc
  • 8.2.6 Grifols S.A
  • 8.2.7 Charles River Laboratories International Inc
  • 8.2.8 RoosterBio Inc
  • 8.2.9 PromoCell GmbH
  • 8.2.10 Danaher Corporation
  • 8.2.11 BioIVT LLC
  • 8.2.12 GeminiBio (Gemini Bioproducts LLC)
  • 8.2.13 Akron Biotech
  • 8.2.14 AllCells LLC
  • 8.2.15 CGT Global